TY -的T1短疗程的资格for multidrug-resistant tuberculosis in Mexico JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02267-2017 VL - 51 IS - 3 SP - 1702267 AU - Munoz-Torrico, Marcela AU - Salazar, Miguel Angel AU - Millán, Miriam de Jesús Mohedano AU - Martínez Orozco, Jose A. AU - Narvaez Diaz, Luis A. AU - Segura del Pilar, Mariela AU - Visca, Dina AU - D'Ambrosio, Lia AU - Centis, Rosella AU - Migliori, Giovanni Battista Y1 - 2018/03/01 UR - //www.qdcxjkg.com/content/51/3/1702267.abstract N2 - We read with interest the articles by Sotgiu et al. [1] and Dalcolmo et al. [2], which initiated a debate on the suitability of the shorter regimen for multidrug-resistant (MDR) tuberculosis (TB) cases in different settings [2–6]. The shorter World Health Organization (WHO) regimen [7, 8] is composed of an initial phase of 4–6 months of kanamycin, moxifloxacin, prothionamide, clofazimine, pyrazinamide, high-dose isoniazid and ethambutol, followed by 5 months of moxifloxacin, clofazimine, pyrazinamide and ethambutol.Comparing phenotypic and genotypic results in Mexico: guidance for the adoption of the shorter MDR-TB regimen http://ow.ly/MOxJ30hXkjd ER -